GlassScriptPhysician profile
Robin A Pingeton
NPI 1154465425
$7,403.03
in general payments reported to CMS, 2019-2025
31 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $858 · 2023: $2,352 · 2024: $1,658 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,503 · Honoraria: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,503.13 |
| Honoraria | $115.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $899.19 | 2023-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $588.01 | 2021-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $572.79 | 2023-2025 | Rexulti |
| Scpharmaceuticals INC. | $532.75 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $482.82 | 2021-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $365.89 | 2021-2023 | |
| Abbvie INC. | $342.55 | 2022-2024 | |
| Boston Scientific Corporation | $339.92 | 2022-2023 | |
| Alpha Cognition USA, INC. | $300.85 | 2025 | Zunveyl |
| Sanofi-Aventis U.S. LLC | $290.28 | 2025 | |
| Novo Nordisk INC | $224.52 | 2022-2024 | Wegovy |
| Viiv Healthcare Company | $205.74 | 2022-2024 | Dovato |
| Glaxosmithkline, LLC. | $193.37 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $186.61 | 2021-2025 | |
| Tris Pharma INC | $183.30 | 2025 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $150.01 | 2023 | Titan |
| Grifols USA, LLC | $135.99 | 2023 | Prolastin-C Liquid |
| Amgen INC. | $128.21 | 2024 | Krystexxa |
| Gilead Sciences, INC. | $125.00 | 2023 | Descovy |
| Urovant Sciences INC | $123.92 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $119.86 | 2025 | Zoryve |
| Horizon Therapeutics Plc | $113.75 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $108.59 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.00 | 2023 | |
| Sun Pharmaceutical Industries INC. | $93.04 | 2021 | |
| Corium, LLC | $92.57 | 2023 | Adlarity |
| Axonics, INC. | $92.56 | 2023 | Bulkamid |
| Impel Pharmaceuticals INC. | $86.25 | 2022 | |
| Alkermes, INC. | $79.38 | 2022 | |
| Scynexis, INC. | $78.85 | 2022 | |
| Medtronic, INC. | $63.46 | 2023 | Inpen Smart Insulin Delivery System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Pingeton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.